178 related articles for article (PubMed ID: 35137541)
1. Recruitment of IL-1β-producing intermediate monocytes enhanced by C5a contributes to the development of malignant pleural effusion.
Luo L; Deng S; Tang W; Hu X; Yin F; Ge H; Tang J; Liao Z; Li X; Feng J
Thorac Cancer; 2022 Mar; 13(6):811-823. PubMed ID: 35137541
[TBL] [Abstract][Full Text] [Related]
2. Anaphylatoxins Enhance Recruitment of Nonclassical Monocytes via Chemokines Produced by Pleural Mesothelial Cells in Tuberculous Pleural Effusion.
Luo L; Li X; Hu X; Hu C; Tang W; Deng S; Feng J
Am J Respir Cell Mol Biol; 2019 Apr; 60(4):454-464. PubMed ID: 30422670
[TBL] [Abstract][Full Text] [Related]
3. Monocytes subtypes from pleural effusion reveal biomarker candidates for the diagnosis of tuberculosis and malignancy.
Luo L; Deng S; Tang W; Hu X; Yin F; Ge H; Tang J; Liao Z; Feng J; Li X; Mo B
J Clin Lab Anal; 2022 Aug; 36(8):e24579. PubMed ID: 35819097
[TBL] [Abstract][Full Text] [Related]
4. C5a enhances inflammation and chemotaxis of γδ T cells in malignant pleural effusion.
Deng S; Jiang Y; Luo L; Tang H; Hu X; Wu C; Tang J; Ge H; Gong X; Cai R; Wang G; Li X; Feng J
Int Immunopharmacol; 2024 Jan; 127():111332. PubMed ID: 38071913
[TBL] [Abstract][Full Text] [Related]
5. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells.
Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z
Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675
[TBL] [Abstract][Full Text] [Related]
6. [Expression of CC-chemokine ligand 18 (CCL18) in the serum and pleural effusion of non-small-cell lung cancer patients and its regulatory effect on the differentiation of monocyte-derived dendritic cells].
Chen L; Zhou Q; Zhong F; Wang Q; Fang Y; Yang K; Guan S
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):823-7. PubMed ID: 25620478
[TBL] [Abstract][Full Text] [Related]
7. Anaphylatoxins orchestrate Th17 response via interactions between CD16+ monocytes and pleural mesothelial cells in tuberculous pleural effusion.
Deng S; Hu X; Luo L; Tang W; Jiang Y; Yin F; Hu C; Feng J; Li X
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009508. PubMed ID: 34237073
[TBL] [Abstract][Full Text] [Related]
8. Mast cells mediate malignant pleural effusion formation.
Giannou AD; Marazioti A; Spella M; Kanellakis NI; Apostolopoulou H; Psallidas I; Prijovich ZM; Vreka M; Zazara DE; Lilis I; Papaleonidopoulos V; Kairi CA; Patmanidi AL; Giopanou I; Spiropoulou N; Harokopos V; Aidinis V; Spyratos D; Teliousi S; Papadaki H; Taraviras S; Snyder LA; Eickelberg O; Kardamakis D; Iwakura Y; Feyerabend TB; Rodewald HR; Kalomenidis I; Blackwell TS; Agalioti T; Stathopoulos GT
J Clin Invest; 2015 Jun; 125(6):2317-34. PubMed ID: 25915587
[TBL] [Abstract][Full Text] [Related]
9. Cytokine/Chemokine/Growth Factor Levels in Malignant Pleural Effusion of Non-small Cell Lung Cancer.
Hayama N; Hattori S; Takahashi G; Takahashi F; Takeuchi T; Tanaka J; Horio Y; Takiguchi H; Tomomatsu K; Kitahara A; Takihara T; Niimi K; Oguma T; Asano K
Tokai J Exp Clin Med; 2020 Dec; 45(4):224-229. PubMed ID: 33300594
[TBL] [Abstract][Full Text] [Related]
10. Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion.
Li X; Wu G; Chen C; Zhao Y; Zhu S; Song X; Yin J; Lv T; Song Y
Front Immunol; 2021; 12():760683. PubMed ID: 34966384
[TBL] [Abstract][Full Text] [Related]
11. Treg/Th17 imbalance in malignant pleural effusion partially predicts poor prognosis.
Yang G; Li H; Yao Y; Xu F; Bao Z; Zhou J
Oncol Rep; 2015 Jan; 33(1):478-84. PubMed ID: 25371165
[TBL] [Abstract][Full Text] [Related]
12. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion.
Wang D; Yang L; Yue D; Cao L; Li L; Wang D; Ping Y; Shen Z; Zheng Y; Wang L; Zhang Y
Cancer Lett; 2019 Jun; 452():244-253. PubMed ID: 30928379
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
[TBL] [Abstract][Full Text] [Related]
14. Variations in pleural microbiota and metabolic phenotype associated with malignant pleural effusion in human lung adenocarcinoma.
Huang D; Zhuo J; Ye C; Su X; Chen Y; Li C; Lin L; Liu L; Zhao H; Luo T; Ren Q; Wu J; Cai S; Dong H
Thorac Cancer; 2023 Jul; 14(21):2045-2056. PubMed ID: 37309281
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of HER-2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as a tumor marker in pleural effusion diagnosis.
Hung TL; Chen FF; Liu JM; Lai WW; Hsiao AL; Huang WT; Chen HH; Su WC
Clin Cancer Res; 2003 Jul; 9(7):2605-12. PubMed ID: 12855637
[TBL] [Abstract][Full Text] [Related]
16. Differentiation and immune regulation of IL-9-producing CD4+ T cells in malignant pleural effusion.
Ye ZJ; Zhou Q; Yin W; Yuan ML; Yang WB; Xiong XZ; Zhang JC; Shi HZ
Am J Respir Crit Care Med; 2012 Dec; 186(11):1168-79. PubMed ID: 23065014
[TBL] [Abstract][Full Text] [Related]
17. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion.
Stathopoulos GT; Sherrill TP; Karabela SP; Goleniewska K; Kalomenidis I; Roussos C; Fingleton B; Yull FE; Peebles RS; Blackwell TS
Am J Respir Crit Care Med; 2010 Nov; 182(10):1273-81. PubMed ID: 20595227
[TBL] [Abstract][Full Text] [Related]
18. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
[TBL] [Abstract][Full Text] [Related]
19. High IL-35 pleural expression in patients with tuberculous pleural effusion.
Dong X; Yang J
Med Sci Monit; 2015 May; 21():1261-8. PubMed ID: 25935866
[TBL] [Abstract][Full Text] [Related]
20. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
